Learn More
PURPOSE Poly(ADP-ribose) polymerase (PARP) inhibitors selectively target homologous recombination (HR)-defective cells and show good clinical activity in hereditary breast and ovarian cancer(More)
Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.Experimental Design: Part 1 (phase(More)
3104 Background: AG-014699 (PF-01367338) is an intravenous, potent, selective PARP-1 and 2 inhibitor (Ki = 1.4 nM). In pre-clinical studies AG-014699 induces selective cytotoxicity in tumour cells(More)